当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

Abstract：

BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cross-sectional and longitudinal analyses were conducted within a prospectively enrolled cohort. We devised a monocyte efficacy (ME) score based on the anticipated effectiveness of ARV medications against monocytes/macrophages using published macrophage in vitro drug efficacy data. We examined, within an HIV neurocognitive database, its association with composite neuropsychological test scores (NPZ8) and clinical cognitive diagnoses among subjects on stable ARV medications unchanged for >6 months prior to assessment. RESULTS:Among 139 subjects on ARV therapy, higher ME score correlated with better NPZ8 performance (r=0.23, P<0.01), whereas a score devised to quantify expected penetration effectiveness of ARVs into the brain (CPE score) did not (r=0.12, P=0.15). In an adjusted model (adjusted r(2)=0.12), ME score (β=0.003, P=0.02), CD4(+) T-cell nadir (β=0.001, P<0.01) and gender (β=-0.456, P=0.02) were associated with NPZ8, whereas CPE score was not (β=0.003, P=0.94). A higher ME score was associated with better clinical cognitive status (P<0.01). With a range of 12.5-433.0 units, a 100-unit increase in ME score resulted in a 10.6-fold decrease in the odds of a dementia diagnosis compared with normal cognition (P=0.01). CONCLUSIONS:ARV efficacy against monocytes/macrophages correlates with cognitive function in HIV-infected individuals on ARV therapy within this cohort. If validated, efficacy against monocytes/macrophages may provide a new target to improve HIV NCI.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

doi

10.3851/IMP2411

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

1233-42

issue

7

eissn

1359-6535

issn

2040-2058

journal_volume

17

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.

    abstract：BACKGROUND:There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B. METHODS:We determined the cumulative virological, serological and biochemical outcomes of 165 lamivudine-resistant chronic hepatitis B patients on la...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2335

    authors： Seto WK,Liu K,Fung J,Wong DK,Yuen JC,Hung IF,Lai CL,Yuen MF

    更新日期：2012-01-01 00:00:00

  • Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

    abstract：BACKGROUND:The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for ne...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,收录出版

    doi：10.3851/IMP3115

    authors： Skarnovich MA,Emelyanova AG,Petrova NV,Borshcheva AA,Gorbunov EA,Mazurkov OY,Skarnovich MO,Tarasov SA,Shishkina LN,Epstein OI

    更新日期：2017-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3851/IMP3205

    authors： Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期：2018-01-01 00:00:00

  • The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

    abstract：BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Bárcena R,Moreno A,del Campo S,Muriel A,Mateos ML,Garrido E,García M,Quereda C,Moreno S,Moreno A

    更新日期：2007-01-01 00:00:00

  • Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

    abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

    更新日期：2008-01-01 00:00:00

  • Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

    abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2570

    authors： Flores MV,Corbau RG,Guionaud S

    更新日期：2013-01-01 00:00:00

  • Finding a role for zalcitabine in the HAART era.

    abstract：:Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. More widespread use of zalcitabine has been limited by a number of factors including peripheral neuropathy and three times daily dosing. However, screening for the risk factors for peripher...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Moyle GJ,Gazzard BG

    更新日期：1998-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期：2007-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract：BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期：2005-01-01 00:00:00

  • Ribavirin considerations in treatment optimization.

    abstract：:Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Dusheiko G,Nelson D,Reddy KR

    更新日期：2008-01-01 00:00:00

  • Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.

    abstract：:We report the first two paediatric cases of sofosbuvir treatment during high-intensity myeloablative conditioning and engraftment phases of haematopoietic stem cell transplantation. These reports highlight the safety of sofosbuvir during all phases of transplantation and the lack of interaction between sofosbuvir and ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3332

    authors： Grasso AG,Sonzogni A,Zanon D,Maestro A,Loiacono S,Maximova N

    更新日期：2019-01-01 00:00:00

  • The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection.

    abstract：:There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Iser DM,Lewin SR

    更新日期：2009-01-01 00:00:00

  • In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.

    abstract：BACKGROUND:Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we inves...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3180

    authors： Baz M,Goyette N,Griffin BD,Kobinger GP,Boivin G

    更新日期：2017-01-01 00:00:00

  • NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.

    abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2326

    authors： Maimone S,Musolino C,Squadrito G,Raffa G,Pollicino T,Raimondo G

    更新日期：2013-01-01 00:00:00

  • Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

    abstract：OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

    更新日期：2007-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract：INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1834

    authors： Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期：2011-01-01 00:00:00

  • Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.

    abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Grollo L,Torresi J,Drummer H,Zeng W,Williamson N,Jackson DC

    更新日期：2006-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract：BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2094

    authors： Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期：2012-01-01 00:00:00

  • Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

    abstract：BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat F

    更新日期：2007-01-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP1489

    authors： European Collaborative Study.

    更新日期：2010-01-01 00:00:00

  • Clinically relevant drug interactions with antiretroviral agents.

    abstract：:With the advent of the human immunodeficiency virus (HIV) protease inhibitors and the non-nucleoside reverse transcriptase inhibitors, the importance of drug-drug interactions with antiretroviral agents is becoming increasingly recognized. Every clinician involved in the care of HIV-infected persons should have a broa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Burger DM,Hoetelmans RM,Koopmans PP,Meenhorst PL,Mulder JW,Hekster YA,Beijnen JH

    更新日期：1997-07-01 00:00:00

  • Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.

    abstract：:We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reachi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yerly S,Denereaz N,Mermillod B,Hirschel B,Perrin L

    更新日期：1996-08-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3036

    authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期：2016-01-01 00:00:00

  • The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

    abstract：:Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2424

    authors： Marks KM,Jacobson IM

    更新日期：2012-01-01 00:00:00

  • Infrequent transmission of HIV-1 drug-resistant variants.

    abstract：:Transmission of drug-resistant variants is influenced by several factors, including the prevalence of drug resistance in the population of HIV-1-infected patients, HIV-1 RNA levels and transmission by recently infected patients. In order to evaluate the impact of these factors on the transmission of drug-resistant var...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yerly S,Jost S,Telenti A,Flepp M,Kaiser L,Chave JP,Vernazza P,Battegay M,Furrer H,Chanzy B,Burgisser P,Rickenbach M,Gebhardt M,Bernard MC,Perneger T,Hirschel B,Perrin L,Swiss HIV Cohort Study.

    更新日期：2004-06-01 00:00:00

  • Drug-drug interactions in HIV therapy: is it all clear?

    abstract：:Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2688

    authors： Burger D,Back D

    更新日期：2013-01-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract：BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3372

    authors： Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期：2020-10-22 00:00:00

  • HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

    abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1982

    authors： Kim BK,Revill PA,Ahn SH

    更新日期：2011-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Fung SK,Lok AS

    更新日期：2004-12-01 00:00:00